LIFEARC

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

1. LIFEARC 2017-06-12 → present
2. MEDICAL RESEARCH COUNCIL TECHNOLOGY 1999-12-23 → 2017-06-12
3. MRC COLLABORATIVE CENTRE 1992-03-18 → 1999-12-23

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Moore Kingston Smith LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.”

Group structure

1. LIFEARC · parent
   1. LifeArc Innovations Limited 100% · England and Wales

Significant events

• “2024 was a pivotal year for LifeArc, marked by significant strides towards tackling underserved conditions. We enhanced our role in bridging the gap between scientific innovation and patients, advancing discoveries that have the potential to transform lives.”
• “A key highlight was our launch of the Childhood Cancer Translational Challenge.”
• “We committed £40 million to establish four Translational Centres for Rare Disease with a range of partners across the country.”
• “We co-founded the UK's first network of Cystic Fibrosis Lung Health Innovation Hubs with Cystic Fibrosis Trust.”
• “We also deepened our commitment to tackling antimicrobial resistance by making a major commitment to, and becoming a founding partner of, the Fleming Initiative.”
• “Dr Sam Barrell joined us as CEO in the autumn, bringing energy, vision and strong leadership.”
• “We have also been joined by our first Chief Medical Officer, Dr Jonathan Morgan.”
• “We collaboratively established a series of translational centres and hubs for both rare disease and lung health with charity, academic and patient partners from around the UK.”
• “We co-started an international drug discovery consortium for childhood cancer.”
• “We funded multiple new clinical trials; conducted our first motor neuron disease community workshops and surveys; and launched our antibody discovery capabilities.”
• “Central to this year's transformation were the strides made in planning for a building in London's King's Cross Knowledge Quarter.”
• “In 2024, we launched our new brand and website, reflecting the evolution of our strategy and position within the translational science ecosystem.”
• “We were also delighted to convene more than 700 attendees for the inaugural LifeArc Translational Science Summit in April.”
• “This included expanding our therapeutics platform to include antibody discovery, with the launch of our advanced B-SMART™ (B cell Screening Method for Antibody Therapeutics) platform.”
• “A major 2024 milestone was joining Britain's largest health research programme, Our Future Health (OFH), as a charity partner.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +29.2%

  £141,321,000 → £182,647,000

• Cash

  +24.2%

  £6,815,000 → £8,462,000

• Net assets

  +16%

  £1,385,478,000 → £1,606,960,000

• Employees

  +19%

  290 → 345

• Wages

  +26.2%

  £22,291,000 → £28,136,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers